Extended Rhythm SCreening for AtRial Fibrillation in Cryptogenic Stroke Patients (SCARF)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2012 by Medisch Spectrum Twente.
Recruitment status was Recruiting
Information provided by (Responsible Party):
B. Oude Velthuis, Medisch Spectrum Twente
First received: March 7, 2012
Last updated: April 20, 2012
Last verified: April 2012
Recent studies demonstrated that prolonged rhythm observation increases the detection of atrial fibrillation in patients prior diagnosed as cryptogenic stroke. Detection of atrial fibrillation in these patients has important therapeutic implications for the anticoagulation regimen. However, data on optimal monitoring duration and method of AF detection are limited.
||Observational Model: Cohort
Time Perspective: Prospective
||Extended Rhythm SCreening for AtRial Fibrillation in Cryptogenic Stroke Patients
Primary Outcome Measures:
Secondary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||September 2012 (Final data collection date for primary outcome measure)
Intensive observation cohort
Patients > 18 years of age diagnosed with a recent episode of cryptogenic stroke with long term rhythm observation using an implantable loop recorder for detecting atrial fibrillation.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients admitted with a ischemic stroke of undetermined etiology
- Patients > 18 years of age Recent episode (≤60 days) of cryptogenic ischemic stroke
- Undetermined etiology with negative evaluation (including cardioembolism work- up) according to the criteria for the Trial of Org 10172 in Acute Stroke Treatment (TOAST)
- Implantation of an implantable loop recorder within two months after index event
- Able of providing informed consent
- Pre-existing indication for vitamin K antagonist
- Untreated hyperthyroidism
- Indication for pacemaker implantation, implantable cardioverter defibrillator (ICD) or Cardiac Resynchronisation Therapy (CRT)
- Severe co-morbidity not likely to complete follow-up for one year
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01550042
|Medisch Spectrum Twente / Thoraxcenter
|Enschede, OV, Netherlands, NL7513ER |
|Contact: Harald Verheij +31534872105 email@example.com |
|Contact: Bob Oude Velthuis, MD MSc +31534872110 firstname.lastname@example.org |
|Principal Investigator: Bob Oude Velthuis, MD MSc |
Medisch Spectrum Twente
||Marcoen Scholten, MD PhD
||Medisch Spectrum Twente
No publications provided
||B. Oude Velthuis, Research fellow electrophysiology, Medisch Spectrum Twente
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 7, 2012
||April 20, 2012
||Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 30, 2015